Chengdu Olymvax Biopharmaceuticals Inc Class A 688319
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CNY 9.73
- Day Range
- CNY 9.59–9.80
- 52-Week Range
- CNY 7.06–25.00
- Bid/Ask
- CNY 9.68 / CNY 9.69
- Market Cap
- CNY 3.94 Bil
- Volume/Avg
- 3.6 Mil / 5.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- 407.14
- Price/Sales
- 7.86
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 440
- Website
- http://www.olymvax.com
Comparables
Valuation
Metric
|
688319
|
688739
|
301207
|
---|---|---|---|
Price/Earnings (Normalized) | 407.14 | 24.95 | 15.84 |
Price/Book Value | 4.40 | 1.17 | 1.82 |
Price/Sales | 7.86 | 6.40 | 5.02 |
Price/Cash Flow | 330.56 | 18.73 | 14.57 |
Price/Earnings
688319
688739
301207
Financial Strength
Metric
|
688319
|
688739
|
301207
|
---|---|---|---|
Quick Ratio | 2.07 | 20.51 | — |
Current Ratio | 2.27 | 22.19 | — |
Interest Coverage | 4.42 | 331.34 | — |
Quick Ratio
688319
688739
301207
Profitability
Metric
|
688319
|
688739
|
301207
|
---|---|---|---|
Return on Assets (Normalized) | −1.80% | 3.62% | 9.39% |
Return on Equity (Normalized) | −3.02% | 3.78% | 11.86% |
Return on Invested Capital (Normalized) | −2.06% | 3.16% | 11.24% |
Return on Assets
688319
688739
301207
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wqxrhvpcf | Mgplg | $590.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bwnclxd | Bylmvv | $113.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hbhlrdgzk | Dzmqhk | $108.0 Bil | |
MRNA
| Moderna Inc | Mxgvypbwz | Xjldr | $54.6 Bil | |
BNTX
| BioNTech SE ADR | Sqvpmjtk | Ttqc | $24.2 Bil | |
ARGX
| argenx SE ADR | Jdbpbxzqt | Ghg | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rvvsccxkx | Gwswx | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vysrrzwr | Bwcjys | $14.3 Bil | |
INCY
| Incyte Corp | Sfjxqwvz | Lyrgtn | $13.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pngmtzthd | Bfmkt | $12.4 Bil |